SHARE:   Share to Facebook Share to Twitter Share to Linked In Share via Email  

Back To Search Results

S31 - MS Therapeutics and Clinical Research II

Event Time: Wednesday April 26, 2017 1:00 pm to 3:00 pm
Topic(s): MS and CNS Inflammatory Disease
Director(s):
Description: A group of abstracts covering a similar topic presented in an oral format. Presentations are eight minutes in length with four minutes of question and answer. Each session concludes with 25 minutes of a discussant bringing additional context to one or more of the abstracts.
Completion Message:
CME Credits: 2
Core Competencies:

Program Speakers - Tentative

Start/End Time Title Faculty
2:35 PM - 3:00 PM Discussion Ellen Mowry MD, FAAN 

Disclosures

Speaker Disclosure
Ellen M. Mowry, MD, FAAN Dr. Mowry has received personal compensation in an editorial capacity for UpToDate (royalties). Dr. Mowry has received research support from Biogen, Genzyme, Teva, SunPharma..

Abstract Presenters

Start Time Pub. Title Presenter
1:00 PM 001 Dalfampiridine improves cognitive impairment in multiple sclerosis (MS): results from a randomised, double-blind, placebo-controlled trial Laura De Giglio
Disclosure:
Dr. De Giglio has received personal compensation for activities with Sanofi Genzyme, Novartis, Biogen, Teva, and EMD Serono.

1:12 PM 002 Rapidity of Onset of Ocrelizumab Clinical Efficacy in Relapsing Multiple Sclerosis Stephen Hauser, MD
Disclosure:
Dr. Hauser serves on the scientific advisory boards for Annexon, Symbiotix, Bionure, and Molecular Stethoscope; serves on the Board of Trustees for Neurona; has received travel reimbursement and writing assistance from F. Hoffmann-La Roche Ltd. for CD20-related meetings..

1:24 PM 003 Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-up Carrie Hersh, DO
Disclosure:
Dr. Hersh has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen Idec, Novartis, Teva, and Genzyme. Dr. Hersh has received research support from Biogen Idec and Genentech.

1:36 PM 004 Preliminary Results of the OPERA I and OPERA II Open-Label Extension Study Robert Naismith, MD
Disclosure:
Dr. Naismith has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Acorda, Alkermes, Bayer, Biogen, EMD Serono, Genentech, Genzyme, Novartis, Teva.. Dr. Naismith has received personal compensation in an editorial capacity for NEJM Journal Watch.

1:48 PM 005 Benign multiple sclerosis in the era of disease modifying therapies Camilo Diaz-Cruz, MD
Disclosure:
Dr. Diaz-Cruz has received research support from EMD Serono and Verily.

2:00 PM 006 Comparison of Natalizumab vs Fingolimod and Dimethyl Fumarate in the Treatment of Multiple Sclerosis: Two Year Experience Brandi Vollmer
Disclosure:
Dr. Vollmer has nothing to disclose.

2:12 PM 007 Alternate dosing of fingolimod for Multiple Sclerosis Ilya Kister, MD
Disclosure:
Dr. Kister has nothing to disclose.

2:24 PM 008 A multicentre, randomized, double-blind, non-inferiority clinical trial to compare the clinical and radiological efficacy of 625 mg versus 1250 mg of oral methylprednisolone in patients with relapse of multiple sclerosis: Oral-CORTEM trial. Ferran Torres
Disclosure:
Dr. Torres has nothing to disclose.

Register Now

Related Courses

Saturday April 21, 2018

9:30 AM-11:30 AM
C11 Treatment of Pediatric Multiple Sclerosis in the Current Era Brenda Banwell MD, FAAN

Sunday April 22, 2018

7:00 AM-9:00 AM
C33 Multiple Sclerosis in the Trenches: Controversy and Consensus in Clinical Decision-Making Aaron Miller MD, FAAN
3:30 PM-5:30 PM
C57 Spanish: Update on MS Therapy Lilyana Amezcua MD

Tuesday April 24, 2018

7:00 AM-9:00 AM
C97 Multiple Sclerosis Overview I: Clinical Pearls John Corboy MD, FAAN
1:00 PM-3:00 PM
C107 Multiple Sclerosis Overview II: Clinical Advances Scott Newsome DO, FAAN
3:30 PM-5:30 PM
C121 Multiple Sclerosis Overview III: Basic and Translational Science Michael Racke MD

Wednesday April 25, 2018

7:00 AM-9:00 AM
C135 Multiple Sclerosis Therapy: Disease-modifying Treatment I David Jones MD
9:15 AM-11:30 AM
PL5 Frontiers in Neuroscience Plenary Session
1:00 PM-3:00 PM
C146 Multiple Sclerosis Therapy: Disease-modifying Treatment II John Rose MD, FAAN
3:30 PM-5:30 PM
C161 Multiple Sclerosis Therapy: Symptom Management Jonathan Carter MD

Thursday April 26, 2018

7:00 AM-9:00 AM
C174 Clinical Pearls in Autoimmune Neurology: Real World Cases Stacey Clardy MD, PhD
1:00 PM-3:00 PM
N5 Neuroscience in the Clinic: Treatment of Progressive Multiple Sclerosis Eric Klawiter MD,
Ellen Mowry MD, FAAN

Friday April 27, 2018

1:00 PM-3:00 PM
C223 Neuromyelitis Optica Spectrum Disorders Dean Wingerchuk MD, FAAN

MEMBER LOG IN

Forgot Password?